Manufacturer or GPO Program year 2025 Source: CMS Open Payments

AstraZeneca UK Limited

Great Britain (UK)

CMS manufacturer 100000010370

Open in the dashboard

General payments

$75,869,023

13,566 payments

Research payments

$550,063,027

11,783 payments

Ownership & investment interest

$0

None reported

Through program year 2025, AstraZeneca UK Limited reported paying $75,869,023 in general payments and $550,063,027 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $5,758,732 2,145
2025 Research $128,571,179 1,692
2024 General $15,422,943 2,356
2024 Research $109,301,966 1,973
2023 General $27,518,345 2,521
2023 Research $118,136,561 1,929
2022 General $20,924,072 1,542
2022 Research $57,624,432 1,737
2021 General $1,405,958 660
2021 Research $69,639,217 1,460
2020 General $2,194,023 1,049
2020 Research $27,066,704 1,084
2019 General $2,644,951 3,293
2019 Research $39,722,967 1,908

Breakdown

Top recipients General payments · program year 2025
  1. University Of Washington Med Ctr Teaching hospital · WA $858,785 7 payments
  2. David Horn Infectious Disease · Philadelphia, PA $359,450 4 payments
  3. Ut Md Anderson Cancer Center Teaching hospital · TX $223,779 1 payment
  4. Dana-Farber Cancer Institute Teaching hospital · MA $165,247 2 payments
  5. National Jewish Health Teaching hospital · CO $115,768 4 payments
  6. Dinesh Khanna Rheumatology · Ann Arbor, MI $101,957 25 payments
  7. Ranya Habash Ophthalmology · Boca Raton, FL $101,300 7 payments
  8. James Wells Critical Care Medicine · Birmingham, AL $82,600 6 payments
  9. John Oppenheimer Allergy · Cedar Knolls, NJ $76,750 8 payments
  10. Surya Seshan New York, NY $67,050 2 payments
Top research recipients Research payments · program year 2025
  1. Global Coalition For Adaptive Research $16,860,000 1 payment
  2. Quantum Leap Healthcare Collaborative $6,619,911 1 payment
  3. Brigham And Womens Hospital Teaching hospital · MA $3,965,641 12 payments
  4. Ut Md Anderson Cancer Center Teaching hospital · TX $3,003,778 8 payments
  5. Omega Research Consultants $1,856,282 6 payments
  6. Alliance For Multispecialty Research $1,666,863 23 payments
  7. Clinical Site Partners INC $1,665,596 2 payments
  8. Jacksonville Center For Clinical Resea $1,618,241 6 payments
  9. Duke Clinical Research Institute $1,562,402 2 payments
  10. Elligo Health Research, Inc $1,527,028 16 payments
Products the payments named General payments · program year 2025
  1. Saphnelo Inflammation and Autoimmunity $609,594 34% · 65 recipients
  2. Breztri Respiratory $253,679 14% · 20 recipients
  3. Datroway Oncology $132,582 7% · 27 recipients
  4. Enhertu Oncology $112,054 6% · 39 recipients
  5. Imfinzi Oncology $110,436 6% · 39 recipients

The top 5 of 17 products; each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

The top 25 products, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $621,430 15% · 122 practitioners
  2. Medical Oncology Internal Medicine $479,676 12% · 134 practitioners
  3. Infectious Disease Internal Medicine $391,474 9% · 8 practitioners
  4. Cardiovascular Disease Internal Medicine $330,115 8% · 46 practitioners
  5. Rheumatology Internal Medicine $320,545 8% · 44 practitioners

The top 5 of 64 specialties; each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Washington $996,461 17% · 12 recipients
  2. Massachusetts $720,636 13% · 80 recipients
  3. Pennsylvania $632,980 11% · 52 recipients
  4. Texas $582,592 10% · 69 recipients
  5. California $501,427 9% · 92 recipients

The top 5 of 40 states; each share is of this company’s general payments in 2025 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $54,245,351 19 payments
  2. Consulting Fee $15,649,632 5,884 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,956,663 267 payments
  4. Travel and Lodging $2,447,145 2,815 payments
  5. Charitable Contribution $296,026 3 payments
  6. Food and Beverage $271,706 4,577 payments
  7. Gift $2,500 1 payment
Companies with a similar name General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP DE, United States $455,882,965
  2. AstraZeneca AB Sweden $6,784,321

Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent.

13,566 general · 11,783 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record